The stock of FibroGen Inc (FGEN) has seen a 8.96% increase in the past week, with a 5.00% gain in the past month, and a 0.43% flourish in the past quarter. The volatility ratio for the week is 9.82%, and the volatility levels for the past 30 days are at 11.13% for FGEN. The simple moving average for the past 20 days is 19.48% for FGEN’s stock, with a -0.87% simple moving average for the past 200 days.
Is It Worth Investing in FibroGen Inc (NASDAQ: FGEN) Right Now?
The 36-month beta value for FGEN is also noteworthy at 0.71. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 5 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for FGEN is 92.39M, and at present, short sellers hold a 7.92% of that float. The average trading volume of FGEN on July 22, 2024 was 2.59M shares.
FGEN) stock’s latest price update
The stock price of FibroGen Inc (NASDAQ: FGEN) has jumped by 10.00 compared to previous close of 1.05. Despite this, the company has seen a gain of 8.96% in its stock price over the last five trading days. globenewswire.com reported 2024-06-03 that SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate FibroGen’s immuno-oncology assets, FG-3165 and FG-3175, in combination with Regeneron’s anti-PD-1 therapy, LIBTAYO® (cemiplimab), in patients with solid tumors.
Analysts’ Opinion of FGEN
Many brokerage firms have already submitted their reports for FGEN stocks, with BofA Securities repeating the rating for FGEN by listing it as a “Underperform.” The predicted price for FGEN in the upcoming period, according to BofA Securities is $2 based on the research report published on August 08, 2023 of the previous year 2023.
FGEN Trading at 5.65% from the 50-Day Moving Average
After a stumble in the market that brought FGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.58% of loss for the given period.
Volatility was left at 11.13%, however, over the last 30 days, the volatility rate increased by 9.82%, as shares sank -0.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.44% lower at present.
During the last 5 trading sessions, FGEN rose by +6.13%, which changed the moving average for the period of 200-days by +52.01% in comparison to the 20-day moving average, which settled at $0.9664. In addition, FibroGen Inc saw 30.32% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FGEN starting from Adib Deyaa, who purchase 22,123 shares at the price of $1.17 back on Jun 12 ’24. After this action, Adib Deyaa now owns 82,123 shares of FibroGen Inc, valued at $25,884 using the latest closing price.
Wettig Thane, the CEO of FibroGen Inc, purchase 50,000 shares at $1.91 during a trade that took place back on Mar 07 ’24, which means that Wettig Thane is holding 470,178 shares at $95,470 based on the most recent closing price.
Stock Fundamentals for FGEN
Current profitability levels for the company are sitting at:
- -1.41 for the present operating margin
- 0.75 for the gross margin
The net margin for FibroGen Inc stands at -1.44. The total capital return value is set at -1.4. Equity return is now at value -42790.17, with -53.17 for asset returns.
Based on FibroGen Inc (FGEN), the company’s capital structure generated -0.87 points at debt to capital in total, while cash flow to debt ratio is standing at -2.57. The debt to equity ratio resting at -0.47. The interest coverage ratio of the stock is -13.04.
Currently, EBITDA for the company is -259.28 million with net debt to EBITDA at -0.29. When we switch over and look at the enterprise to sales, we see a ratio of 1.09. The receivables turnover for the company is 2.55for trailing twelve months and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.41.
Conclusion
In summary, FibroGen Inc (FGEN) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
